Transarterial chemoembolization and sorafenib in hepatocellular carcinoma

Expert Review of Anticancer Therapy

Volumn 14, Issue 7, 2014, Pages 831-845

  Cabibbo, Giuseppe ^a   Tremosini, Silvia ^b   Galati, Giovanni ^c   Mazza, Giancarlo ^d   Gadaleta Caldarola, Gennaro ^e   Lombardi, Giuseppe ^f   Antonucci, Michela ^a   Sacco, Rodolfo ^g  

^a UNIVERSITY OF PALERMO   (Italy)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d University and Civil Hospital of Brescia   (Italy)

^e Medical Oncology Unit Mons R Dimiccoli Hospital   (Italy)

^f VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^g UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Combination therapy; HCC; Intermediate stage; Sorafenib; TACE

Indexed keywords

DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; MITOMYCIN; OXALIPLATIN; PLACEBO; SORAFENIB; YTTRIUM 90; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ALOPECIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CLINICAL PROTOCOL; DIARRHEA; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SKIN MANIFESTATION; SKIN TOXICITY; STANDARDIZATION; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL (TOPIC); LIVER NEOPLASMS; PROCEDURES;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CLINICAL TRIALS AS TOPIC; HUMANS; LIVER NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 84903213593     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2014.920694     Document Type: Review

References (84)

1. Cabibbo G, Craxì A. Hepatocellular cancer: Optimal strategies for screening and surveillance. Dig Dis 2009;27:142-7
2. European Association for the Study of the Liver, European Organization for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2012;56:908-43
3. Cabibbo G, Rolle E, De Giorgio M, et al. Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. Expert Rev Anticancer Ther 2011;11:1807-16
4. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010;52:762-73
5. Lencioni R, Chen XP, Dagher L,Venook AP. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: How can outcomes be improved?. Oncologist 2010;15:42-52
6. Cammà C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-Analysis of randomized controlled trials. Radiology 2002;224:47-54 (Pubitemid 34680374)
7. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-42 (Pubitemid 36152543
8. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48:S20-37
9. EMA; Nexavar. EPAR - Product Information - European Medicines Agency - Annex I summary of product characteristics. 2011. Available from: Www. ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000690/ WC500027704.pdf
10. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
11. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind,placebo-controlled trial. Lancet Oncol 2009;10:25-34
12. Raoul JL, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011;37:212-20
13. Sung Wook Shin. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol 2009;10:425-34
14. Cabibbo G, Maida M, Genco C, et al. Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. World J Hepatol 2012;4:256-61
15. Cabibbo G, Enea M, Attanasio M, et al. A meta-Analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010;51:1274-83
16. Combescure C, Foucher Y, Jackson D. Meta-Analysis of single-Arm survival studies: A distribution-free approach for estimating summary survival curves with random effects. Stat Med 2014. [Epub ahead of print]
17. Piscaglia F, Bolondi L. The intermediate hepatocellular 0carcinoma stage: Should treatment be expanded?. Dig Liver Dis 2010;42:S258-63
18. Bolondi L, Burroughs A, Dufour JF, et al. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis 2012;32:348-59
19. Sacco R, Bertini M, Petruzzi P, et al. Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: A cohort study. World J Gastroenterol 2009;15:1843-8
20. Dufour JF, Bargellini I, De Maria N, et al. Intermediate hepatocellular carcinoma: Current treatments and future perspectives. Ann Oncol 2013;24:ii24-9
21. Sacco R, Bargellini I, Bertini M, et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2011;22:1545-52
22. Italian Association for the Study of the Liver (AISF); AISF Expert Panel; AISF Coordinating Committee. Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. Dig Liver Dis 2013;45:712-13
23. Bargellini I, Florio F, Golfieri R, et al. Trends in utilization of transarterial treatments for hepatocellular carcinoma: Results of a survey by the Italian Society of Interventional Radiology. Cardiovasc Intervent Radiol 2014;37(2):438-44
24. Cabibbo G, Latteri F, Antonucci M,Craxì A. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Clin Pract Gastroenterol Hepatol 2009;6: 159-69
25. Finn RS. Emerging targeted strategies in advanced hepatocellular carcinoma. Semin Liver Dis 2013;33:S11-19
26. Sergio A, Cristofori C, Cardin R, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): The role of angiogenesis and invasiveness. Am J Gastroenterol 2008;103: 914-92
27. Li X, Feng GS, Zheng CS, et al. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 2004;10:2878-82 (Pubitemid 39303010
28. Xiong ZP, Yang SR, Liang ZY, et al. Association between vascular endothelial growth factor and metastasis after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2004;3: 386-90
29. Dufour JF. TACE with or without systemic therapy?. J Hepatol 2012;56:1224-5
30. Dufour JF, Hoppe H, Heim MH, et al. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: Results of a phase I study. Oncologist 2010;15:1198-204
31. Sieghart W, Pinter M, Reisegger M, et al. Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: A pilot study. Eur Radiol 2012;22:1214-23
32. Park JW, Koh YH, Kim HB, et al. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol 2012;56:1336-42
33. Chung YH, Han G, Yoon JH, et al. Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. Int J Cancer 2013;132:2448-58
34. Han G, Yang J, Shao G, et al. Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: A subgroup interim analysis of the START trial. Future Oncol 2013;9:403-10
35. Muhammad A, Dhamija M, Vidyarthi G,et al. Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma. World J Hepatol 2013;5:364-71
36. Qu XD, Chen CS, Wang JH, et al. The efficacy of TACE combined sorafenib in advanced stages hepatocellular carcinoma. BMC Cancer 2012;12:263
37. Bai W, Wang YJ, Zhao Y, et al. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: A propensity score matching study. J Dig Dis 2013;14:181-90
38. Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011;47:2117-27
39. Sansonno D, Lauletta G, Russi S, et al. Transarterial chemoembolization plus sorafenib: A sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: A randomized clinical trial. Oncologist 2012;17:359-66
40. Pawlik TM, Reyes DK, Cosgrove D, et al. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 2011;29:3960-7
41. Cabrera R, Pannu DS, Caridi J, et al. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther 2011;34:205-13
42. Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized,double-blind SPACE trial. J Clin Oncol 2012;30(4):LBA154
43. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33:41-52
44. Malagari K, Pomoni M, Moschouris H,et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: Five-year survival analysis. Cardiovasc Intervent Radiol 2012;35:1119-28
45. Maida M, Cabibbo G, Brancatelli G, et al. Assessment of treatment response in hepatocellular carcinoma: A review of the literature. Future Oncol 2013;9:845-54
46. Cabibbo G, Genco C, Di Marco V, et al. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. Aliment Pharmacol Ther 2011;34:196-204
47. Cabibbo G, Maida M, Genco C, et al. Survival of patients with hepatocellular carcinoma (HCC) treated by percutaneous radio-frequency ablation (RFA) is affected by complete radiological response. PLoS One 2013;8:e70016
48. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7: 3129-40
49. Wang B, Xu H, Gao ZQ, et al. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 2008;49:523-9
50. Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011;91:1071-121
51. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005;307: 58-62 (Pubitemid 40093472
52. Jiang H, Meng Q, Tan H, et al. Antiangiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas. Int J Cancer 2007;121:416-24 (Pubitemid 46917712
53. Lencioni R, Kudo M, Ye SL, et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): Second interim analysis. Int J Clin Pract 2014;68(5):609-17
54. Stal PI, Bronowicki JP, Mathurin P, et al. Real-life management of HCC with sorafenib and TACE in Europe from GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib). Poster n 2013; P1196
55. Abou-Alfa GK. TACE and sorafenib: A good marriage?. J Clin Oncol 2011;29: 3949-52
56. Iavarone M, Cabibbo G, Piscaglia F, et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy. Hepatology 2011;54:2055-63
57. Cabibbo G, Maida M, Cammà C, Craxì A. Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?. Expert Rev Anticancer Ther 2013;13:1355-61
58. Sacco R, Bargellini I, Ginanni B, et al. Long-Term results of sorafenib in advanced-stage hepatocellular carcinoma: What can we learn from routine clinical practice?. Expert Rev Anticancer Ther 2012;12:869-75
59. Choi GH, Shim JH, Kim MJ, et al. Sorafenib Alone versus Sorafenib Combined with Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: Results of Propensity Score Analyses. Radiology 2013;269:603-11
60. Zhao Y, Wang WJ, Guan S, et al. Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: A large-scale multicenter study of 222 patients. Ann Oncol 2013;24:1786-92
61. ClinicalTrials.gov. Available from: Http://clinicaltrials.gov/show/ NCT01906216
62. ClinicalTrials.gov. Available from: Http://clinicaltrials.gov/ct2/show/ NCT01409499
63. ClinicalTrials.gov. Available from: Http://clinicaltrials.gov/show/ NCT01829035
64. ClinicalTrials.gov. Available from: Http://clinicaltrials.gov/ct2/show/ NCT01480817
65. Borzio M, Fornari F, De Sio I, et al. Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: Results of an Italian field practice multicenter study. Future Oncol 2013;9: 283-94
66. Borzio M, Sacco R. Nonadherence to guidelines in the management of hepatocellular carcinoma: An Italian or universal phenomenon?. Future Oncol 2013;9:465-7
67. ClinicalTrials.gov. Available from: Http://clinicaltrials.gov/ct2/show/ NCT00768937
68. ClinicalTrials.gov. Available from: Http://clinicaltrials.gov/ct2/show/ NCT00618384
69. ClinicalTrials.gov. Available from: Http://clinicaltrials.gov/show/ NCT00576056
70. ClinicalTrials.gov. Available from: Http://clinicaltrials.gov/show/ NCT01833299
71. ClinicalTrials.gov. Available from: Http://clinicaltrials.gov/show/ NCT01933945
72. ClinicalTrials.gov. Available from: Http://clinicaltrials.gov/ct2/show/ NCT00478374
73. ClinicalTrials.gov. Available from: Http://clinicaltrials.gov/show/ NCT00494299
74. ClinicalTrials.gov. Available from: Http://clinicaltrials.gov/show/ NCT00919009
75. ClinicalTrials.gov. Available from: Http://clinicaltrials.gov/ct2/show/ NCT01605734
76. ClinicalTrials.gov. Available from: Http://clinicaltrials.gov/ct2/show/ NCT00844883
77. ClinicalTrials.gov. Available from: Http://clinicaltrials.gov/show/ NCT01556815
78. ClinicalTrials.gov. Available from: Http://clinicaltrials.gov/ct2/show/ NCT00855218
79. ClinicalTrials.gov. Available from: Http://clinicaltrials.gov/show/ NCT01901692
80. ClinicalTrials.gov. Available from: Http://clinicaltrials.gov/ct2/show/ NCT01839630
81. ClinicalTrials.gov. Available from: Http://clinicaltrials.gov/ct2/show/ NCT01217034/82. ClinicalTrials.gov. Available from: Http://clinicaltrials.gov/ show/NCT01004978
82. ClinicalTrials.gov. Available from: Www. clinicaltrials.gov/ct2/show/ NCT01011010
83. ClinicalTrials.gov. Available from: Http://clinicaltrials.gov/show/ NCT01042041
84. ClinicalTrials.gov. Available from: Http://clinicaltrials.gov/ct2/show/ NCT01324076.